View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

   reports
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Georg Tigalonov-Bjerke
HNSA HANSA BIOPHARMA AB
07/22/25 July 22, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Georg Tigalonov-Bjerke
HNSA HANSA BIOPHARMA AB
07/17/25 July 17, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
HNSA HANSA BIOPHARMA AB
04/24/25 April 24, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
HNSA HANSA BIOPHARMA AB
04/24/25 April 24, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
HNSA HANSA BIOPHARMA AB
04/11/25 April 11, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
HNSA HANSA BIOPHARMA AB
02/07/25 February 7, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
HNSA HANSA BIOPHARMA AB
02/06/25 February 6, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
HNSA HANSA BIOPHARMA AB
01/13/25 January 13, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
HNSA HANSA BIOPHARMA AB
12/18/24 December 18, 2024 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
HNSA HANSA BIOPHARMA AB
12/03/24 December 3, 2024 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
HNSA HANSA BIOPHARMA AB
10/18/24 October 18, 2024 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
HNSA HANSA BIOPHARMA AB
10/17/24 October 17, 2024 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
HNSA HANSA BIOPHARMA AB
10/08/24 October 8, 2024 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
HNSA HANSA BIOPHARMA AB
10/07/24 October 7, 2024 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
PREMIUM
HNSA Hansa Biopharma...

Stable quarter but time to grow in H2

EU adj. sales development neutral. Cash burn to improve in H2 after one-offs in Q2. Revising our model: BUY, TP SEK 88 (98).

HNSA HANSA BIOPHARMA AB
07/19/24 July 19, 2024 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
HNSA HANSA BIOPHARMA AB
07/18/24 July 18, 2024 1 EN
Maria Vara ... (+2)
  • Maria Vara
  • Oscar Haffen Lamm
PREMIUM
IPN IPSEN SA
CLLS CELLECTIS ADS ... (+19)

End of coverage

From 5th February, we will no longer include in our research universe:Adaptimmune, ALK, argenx, Autolus, Cellectis, Galapagos, Hansa Biopharma, Heidelberg Pharma, Immatics, Immunocore, Ipsen, Moonlake Immunotherapeutics, Pharvaris, UCB, Vivoryon Therapeutics, Zealand Pharma, Nicox, GenSight Biologi

IPN IPSEN SA
CLLS CELLECTIS ADS
ADAP ADAPTIMMUNE THERAPEUTICS ADS
ANZ AUSTRALIA AND NEW ZEALAND BANKING GROUP LIMITED
HPHA HEIDELBERG PHARMA AG
COX NICOX SA
UCB UCB S.A.
HNSA HANSA BIOPHARMA AB
SIGHT GENSIGHT BIOLOGICS SA
ALSEN SENSORION SAS
ALKb ALK-ABELLO
ARGX ARGEN-X SE
AUTL AUTOLUS THERAPEUTICS ADS
IMCR IMMUNOCORE HOLDINGS ADS
PHVS PHARVARIS NV
MLTX MOONLAKE IMMUNOTHERAPEUTICS
IMTX IMMATICS
GLG GALAPAGOS
VVY VIVORYON THERAPEUTICS
02/05/24 February 5, 2024 1 EN
Alex Cogut
  • Alex Cogut
PREMIUM
HNSA Hansa Biopharma...

More execution challenges, downgrading to SELL

Hansa recently announced the first results from its 2nd gen product, HNSA-5487, which did not actually give an answer to its repeat dosing potential and likely will not be clear even with all data analysed in 2024. While we believe that HNSA-5487 is the real value in the company, the lack of clarit

HNSA HANSA BIOPHARMA AB
10/13/23 October 13, 2023 1 EN
Alex Cogut
  • Alex Cogut
PREMIUM
OSE OSE Immunothera...
CLLS CELLECTIS ADS ... (+18)

Coverage update

Given team and strategy changes, Alex Cogut is now assuming coverage of Achilles Therapeutics, Adaptimmune Therapeutics, Autolus, Calliditas, Cellectis, Galapagos, GenSight, Hansa Biopharma, Heidelberg Pharma, Immunocore, Innate Pharma, Sesorion and ValerioWe drop coverage of Celyad Oncology BioNte

OSE OSE IMMUNOTHERAPEUTICS SA
CLLS CELLECTIS ADS
ADAP ADAPTIMMUNE THERAPEUTICS ADS
TNG TRANSGENE SA
IPH INNATE PHARMA SA CLASS A
CYAD CELYAD ONCOLOGY
HNSA HANSA BIOPHARMA AB
SIGHT GENSIGHT BIOLOGICS SA
5142 ACHILLES CORP.
POXEL POXEL SA
BCART BIOCARTIS GROUP NV
CRSP CRISPR THERAPEUTICS AG
GNMSY GENMAB A/S
BNTX BIONTECH SE
CALTX CALLIDITAS THERAPEUTICS AB
IMCR IMMUNOCORE HOLDINGS ADS
IMTX IMMATICS
GLG GALAPAGOS
09/28/23 September 28, 2023 1 EN
Healthcare Team
  • Healthcare Team
HNSA HANSA BIOPHARMA AB
MLTX MOONLAKE IMMUNOTHERAPEUTICS
04/20/23 April 20, 2023 1 EN
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest
Save

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search
Save

ResearchPool Subscriptions

Get the most out of your insights

Get in touch